Endo International plc (ENDP)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.99-1.40 (-5.99%)
At close: 4:00 PM EDT
People also watch:
VRXPRGOMYLALXNUTHR
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open23.29
Prev Close23.39
Bid21.56 x 400
Ask22.04 x 200
Day's Range21.77 - 23.44
52wk Range12.56 - 72.85
1y Target EstN/A
Market Cap4.9B
P/E Ratio (ttm)-5.03
Beta0.35
Volume7,829,101
Avg Vol (3m)7,179,579
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • TheStreet.com8 hours ago

    Endo (ENDP) Stock Slumps, Oppenheimer: 'Not Surprised' by CEO Change

    Oppenheimer analysts say Endo's (ENDP) recent management shake-up indicates the company is re-focusing on its generics business, rather than M&As.

  • Barrons.com9 hours ago

    Endo: The Good Feelings Didn't Last Long, Did They?

    Last Friday, Endo International's (ENDP) stock soared 15% after the specialty pharmaceutical company announced that it had replaced CEO Rajiv De Silva with Paul Campanelli. Oppenheimer's Marcus Ho says the CEO change "signals [a] new direction for Endo." He explains why: We were not entirely surprised by the move as Endo has been especially hit hard by both the recent negative commentary surrounding opioids and the erosion in the generics pricing environment. Management reaffirmed 3Q and full-year 2016 guidance and is now directionally focused more on operational execution vs. business development, with an emphasis on pipeline and paragraph IV opportunities on the generics side and product development (e.g., Xiaflex) on the branded side... In terms of its strategy for the generics portfolio, Endo plans on building out a "differentiated portfolio," assessing opportunities on a product-by-product basis (with a focus on alternative dosage forms), as opposed to emphasizing scale on what's largely considered a commoditized business.

  • Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps
    Zacks13 hours ago

    Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps

    Endo International's (ENDP) shares soared 15.5% after the company appointed Paul V. Campanelli as the new President and Chief Executive Officer; guidance intact.